US HHS Says 8 Labs Sign Royalty-Free Agreements For H5N1 Tests; Moderna Deal Allows Pivot To Other Pandemic Threats; Too Early To Determine Moderna Vaccine Production Capacity; First H5N1 Vaccines From CSL Seqirus Ready By Mid-July
US HHS Says 8 Labs Sign Royalty-Free Agreements For H5N1 Tests; Moderna Deal Allows Pivot To Other Pandemic Threats; Too Early To Determine Moderna Vaccine Production Capacity; First H5N1 Vaccines From CSL Seqirus Ready By Mid-July
美國HHS表示已有8家實驗室簽署無版稅協議進行H5N1測試；moderna的交易允許應對其他大流行病威脅；現在判斷moderna疫苗的生產能力還爲時過早；來自CSL Seqirus的首批H5N1疫苗將於7月中旬準備就緒。
US HHS Says 8 Labs Sign Royalty-Free Agreements For H5N1 Tests; Moderna Deal Allows Pivot To Other Pandemic Threats; Too Early To Determine Moderna Vaccine Production Capacity; First H5N1 Vaccines From CSL Seqirus Ready By Mid-July
美國HHS表示已有8家實驗室簽署無版稅協議進行H5N1測試；moderna的交易允許應對其他大流行病威脅；現在判斷moderna疫苗的生產能力還爲時過早；來自CSL Seqirus的首批H5N1疫苗將於7月中旬準備就緒。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。